Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rang in aandelen #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Aandeelprijs
$1.89
Laatst gesynchroniseerd: 2022-12-16
Marktkapitalisatie
$24.38M
Verandering (1 dag)
8.62%
Verandering (1 jaar)
0.00%
Land
US
Handel Yumanity Therapeutics, Inc. (YMTX)

Categorie

Koersgeschiedenis voor Yumanity Therapeutics, Inc. (YMTX)
Hoogste slotkoers: $1.94 op 2022-12-01

Laagste slotkoers: $18.35 op 2020-12-01
Koersgeschiedenis van Yumanity Therapeutics, Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2022 -41.89%
2021 -81.82%
2020 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$552.07 41.28%
US
$168.77 504.69%
US
$1.03K 57.19%
NL
$117.42 -19.34%
AU
$753.28 8.59%
CH